DEXCEL-PHARMA LIMITED
Get an alert when DEXCEL-PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-06-30
Confirmation statement due
2026-09-06 (in 4mo)
Last made up 2025-08-23
Watchouts
None on the register
Cash
£2M
-25.1% vs 2023
Net assets
£22M
+54.5% highest in 5 filed years
Employees
22
+4.8% highest in 5 filed years
Profit before tax
£2M
-32.1% first positive since 2019
Net assets
8-year trend · vs Consumer Discretionary median
Accounts
8-year trend · latest reflected 2024-06-30
| Metric | Trend | 2019-01-01 | 2019-12-31 | 2020-12-31 | 2021-01-01 | 2021-12-31 | 2022-01-01 | 2023-06-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | — | £10,426,745 | £14,650,829 | — | £17,067,261 | — | £27,584,426 | £21,547,541 | |
| Operating profit | — | -£4,489,117 | £395,631 | — | £837,649 | — | £2,852,345 | £1,845,499 | |
| Profit before tax | — | -£4,477,260 | £401,984 | — | £837,649 | — | £2,852,345 | £1,936,861 | |
| Net profit | — | -£4,479,513 | £446,756 | — | £837,649 | — | £2,331,070 | £1,470,991 | |
| Cash | — | £6,268,409 | £841,337 | — | £2,289,536 | — | £3,196,746 | £2,393,049 | |
| Total assets less current liabilities | — | £10,545,453 | £10,992,209 | — | £11,829,858 | — | £14,160,928 | £28,745,280 | |
| Net assets | — | £10,545,453 | £10,992,209 | — | £11,829,858 | — | £14,160,928 | £21,880,858 | |
| Equity | £15,024,966 | £10,545,453 | £10,992,209 | £10,992,209 | £11,829,858 | £11,829,858 | £14,160,928 | £21,880,858 | |
| Average employees | — | 20 | 20 | — | 20 | — | 21 | 22 | |
| Wages | — | £1,035,961 | £1,045,451 | — | £1,208,140 | — | £1,822,983 | £1,428,011 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2019-01-01 | 2019-12-31 | 2020-12-31 | 2021-01-01 | 2021-12-31 | 2022-01-01 | 2023-06-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | — | -43.1% | 2.7% | — | 4.9% | — | 10.3% | 8.6% | |
| Net margin | — | -43.0% | 3.0% | — | 4.9% | — | 8.5% | 6.8% | |
| Return on capital employed | — | -42.6% | 3.6% | — | 7.1% | — | 20.1% | 6.4% | |
| Current ratio | — | — | — | — | — | — | 2.49x | 2.87x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- MHA
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company is profitable and continues to be profitable post year end, as well as holding a strong working capital position. Based on the continued profitability and working capital position, the directors consider the Company has the ability to continue as a going concern for the next 12 months and therefore these financial statements have been prepared on a going concern basis. No material uncertainty in relation to going concern has been identified.”
Significant events
- “There have been no significant events affecting the Company since the year end.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KONSTANTINOU, Anastasis | Director | 2014-06-24 | Jul 1984 | Cypriot |
| RIDSDALE, Andrew John | Director | 2022-05-23 | Mar 1971 | British |
| SEELENFREUND, Yigal | Director | 2022-05-23 | Aug 1967 | Israeli |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GRIGG, Terry Kenneth | Secretary | 2010-05-10 | 2022-05-23 |
| KAPPLER, Michael Roy | Secretary | 1997-01-21 | 2010-05-10 |
| MOORE, Debbie | Nominee Secretary | 1994-08-31 | 1994-08-31 |
| SECRETARIAL SERVICES LIMITED | Corporate Secretary | 1994-08-31 | 1997-01-21 |
| AVRAHAM, Dov | Director | 2011-08-01 | 2014-06-24 |
| BROWN, Kevin Thomas | Nominee Director | 1994-08-31 | 1994-08-31 |
| CARMELI, Liel | Director | 1996-10-31 | 2011-08-01 |
| GRIGG, Terry | Director | 2006-05-16 | 2022-05-23 |
| KAPPLER, Michael Roy | Director | 1996-10-31 | 2010-05-10 |
| MILLNER, Harry | Director | 1996-10-31 | 2002-11-05 |
| OREN, Dan | Director | 1994-08-31 | 2022-05-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dexcel Pharma Laboratories Ltd | Corporate entity | Shares 75–100% | 2016-08-23 | Active |
Filing timeline
Last 20 of 100 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-11-13 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-11-04 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-09-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-19 | AA01 | accounts | Change account reference date company | |
| 2025-03-28 | AA | accounts | Accounts with accounts type full | |
| 2024-08-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-03-28 | AA | accounts | Accounts with accounts type full | |
| 2023-09-14 | AA01 | accounts | Change account reference date company previous extended | |
| 2023-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-30 | AA | accounts | Accounts with accounts type full | |
| 2022-08-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-05-25 | AP01 | officers | Appoint person director company with name date | |
| 2022-05-24 | AP01 | officers | Appoint person director company with name date | |
| 2022-05-24 | TM01 | officers | Termination director company with name termination date | |
| 2022-05-24 | TM01 | officers | Termination director company with name termination date | |
| 2022-05-24 | TM02 | officers | Termination secretary company with name termination date | |
| 2021-12-24 | AA | accounts | Accounts with accounts type full | |
| 2021-08-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-02-22 | AA | accounts | Accounts with accounts type full | |
| 2020-08-24 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-06-30 vs 2023-06-30
-
Turnover
-21.9%
£27,584,426 £21,547,541
-
Cash
-25.1%
£3,196,746 £2,393,049
-
Net assets
+54.5%
£14,160,928 £21,880,858
highest in 5 filed years
-
Employees
+4.8%
21 22
highest in 5 filed years
-
Operating profit
-35.3%
£2,852,345 £1,845,499
first positive since 2019
-
Profit before tax
-32.1%
£2,852,345 £1,936,861
first positive since 2019
-
Wages
-21.7%
£1,822,983 £1,428,011
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers